Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adynxx, Inc.ADYX · Entity 155807 | CHIEF MEDICAL OFFICER | May 03, 2019 | May 07, 2019 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Medical Officer | June 09, 2021 | June 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adynxx, Inc.
Report date May 03, 2019 · Filed May 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2022-03-07 | Direct | 23,858 |
Reported balance
After 2019-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-03 · Grant · Acquired 23,858 · Balance 23,858 F1: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F2: (2) On March 8, 2012, Reporting Person was granted an option to purchase 664,560 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,858 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2022-07-16 | Direct | 7,887 |
Reported balance
After 2019-05-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-03 · Grant · Acquired 7,887 · Balance 7,887 F1: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F3: (3) On July 17, 2012, Reporting Person was granted an option to purchase 219,684 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,887 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2022-12-17 | Direct | 3,943 |
Reported balance
After 2019-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-03 · Grant · Acquired 3,943 · Balance 3,943 F1: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F4: (4) On December 18, 2012, Reporting Person was granted an option to purchase 109,842 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,943 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2026-12-15 | Direct | 56,407 |
Reported balance
After 2019-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-05-03 · Grant · Acquired 56,407 · Balance 56,407 F1: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F5: (5) On December 16, 2016, Reporting Person was granted an option to purchase 1,571,214 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 56,407 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding.
F2: (2) On March 8, 2012, Reporting Person was granted an option to purchase 664,560 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,858 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested.
F3: (3) On July 17, 2012, Reporting Person was granted an option to purchase 219,684 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,887 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
F4: (4) On December 18, 2012, Reporting Person was granted an option to purchase 109,842 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,943 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested.
F5: (5) On December 16, 2016, Reporting Person was granted an option to purchase 1,571,214 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 56,407 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable.
Pacira BioSciences, Inc.
Report date June 09, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,520 |
Reported balance
After 2021-06-09 transaction · row 1
1 source rowRow 1 · 2021-06-09 · Grant · Acquired 6,000 · Balance 29,520 F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2031-06-09 | Direct | 15,000 |
Reported balance
After 2021-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-09 · Grant · Acquired 15,000 · Balance 15,000 F2: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2021 Filed Jun 11, 2021 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040088 · doc4.xml · derivative · entry 2 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040088 · doc4.xml · nonDerivative · entry 1 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,520 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 18:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,600 | $61.14 | $158,964.00 |
DisclosureSEC source: 0001209191-21-039610 · doc4.xml · nonDerivative · entry 1 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,520 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.130 to $61.175, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 17:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,380 | $62.12 | $147,852.74 |
DisclosureSEC source: 0001209191-21-038328 · doc4.xml · nonDerivative · entry 1 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,120 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 71,300 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-20-034450 · doc4.xml · derivative · entry 2 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,300 Underlying: Common Stock · 71,300 shares Expires 2030-06-02 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on May 1, 2021, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 28,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034450 · doc4.xml · nonDerivative · entry 1 Manning Donald C. · CIK 0001775268 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 1, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:55 UTC | Adynxx, Inc. ADYX · Entity 155807 | GrantStock Option (Right to Buy) · Derivative | 56,407 | Not disclosed Strike: $3.06 | Not disclosed |
DisclosureSEC source: 0001209191-19-028146 · doc4.xml · derivative · entry 4 Manning Donald C. · CIK 0001775268 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,407 Underlying: Common Stock · 56,407 shares Expires 2026-12-15 F1 · kind: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F5 · price: (5) On December 16, 2016, Reporting Person was granted an option to purchase 1,571,214 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 56,407 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable. F5 · derivative.exercise_date: (5) On December 16, 2016, Reporting Person was granted an option to purchase 1,571,214 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 56,407 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:55 UTC | Adynxx, Inc. ADYX · Entity 155807 | GrantStock Option (Right to Buy) · Derivative | 3,943 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001209191-19-028146 · doc4.xml · derivative · entry 3 Manning Donald C. · CIK 0001775268 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,943 Underlying: Common Stock · 3,943 shares Expires 2022-12-17 F1 · kind: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F4 · price: (4) On December 18, 2012, Reporting Person was granted an option to purchase 109,842 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,943 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. F4 · derivative.exercise_date: (4) On December 18, 2012, Reporting Person was granted an option to purchase 109,842 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,943 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:55 UTC | Adynxx, Inc. ADYX · Entity 155807 | GrantStock Option (Right to Buy) · Derivative | 7,887 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001209191-19-028146 · doc4.xml · derivative · entry 2 Manning Donald C. · CIK 0001775268 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,887 Underlying: Common Stock · 7,887 shares Expires 2022-07-16 F1 · kind: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F3 · price: (3) On July 17, 2012, Reporting Person was granted an option to purchase 219,684 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,887 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. F3 · derivative.exercise_date: (3) On July 17, 2012, Reporting Person was granted an option to purchase 219,684 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,887 shares of the Issuer's common stock at a per share exercise price of $1.39. This option has fully vested. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:55 UTC | Adynxx, Inc. ADYX · Entity 155807 | GrantStock Option (Right to Buy) · Derivative | 23,858 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001209191-19-028146 · doc4.xml · derivative · entry 1 Manning Donald C. · CIK 0001775268 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,858 Underlying: Common Stock · 23,858 shares Expires 2022-03-07 F1 · kind: (1) Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock, reflecting a reverse stock split at a ratio of one new share for every six shares of common stock outstanding. F2 · price: (2) On March 8, 2012, Reporting Person was granted an option to purchase 664,560 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,858 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested. F2 · derivative.exercise_date: (2) On March 8, 2012, Reporting Person was granted an option to purchase 664,560 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.04 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 23,858 shares of the Issuer's common stock at a per share exercise price of $1.11. This option has fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.